PDG Technology^TM is the key solution to challenges faced by pharmaceutical companies in development of solid oral dosage forms. The technology replaces existing solid dosage form development and manufacturing technologies, offering more rapid development and better quality. The unique capabilities of the technology have been demonstrated in number of evaluation studies with top-tier pharmaceutical companies.

 The PDG Technology^TM: 

• Is based on a pneumatic dry granulation process, a novel dry method for automatic or semi-automatic production of granules,
• Enables flexible modification of drug load, disintegration time and tablet hardness,
• Can achieve:
• High drug loading, even with ‘difficult' APIs and combinations
• Taste masking
• Excellent stability,
• Is compatible with other technologies, such as sustained release, fast release, coating,
• Is suitable for heat labile and moisture sensitive drugs, and
• Is the subject of a number of patent applications.

 PDG Technology^TM is available for licensing.

Atacama Labs Oy has internally developed a set of generic fast-release and ODT formulations. The company has filed number of patent applications to protect the new formulations, and is looking for partners to productize the formulations and to bring them to the market. Generic companies are also welcome to contact Atacama Labs Oy regarding feasibility studies on target generic APIs.